Yoshiaki Nakamura Selected Research

Circulating Tumor DNA

4/2022	DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy.
1/2022	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
1/2022	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
1/2022	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
1/2022	Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database.
11/2021	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
10/2021	Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
10/2021	[Clinical Utility of Circulating Tumor DNA Analysis for Precision Medicine in Patients with Advanced Gastrointestinal Cancer].
8/2021	Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases.
8/2021	ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve "Precision Onco-Surgery" in Resectable Colorectal Liver Metastases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshiaki Nakamura Research Topics

Disease

41	Neoplasms (Cancer) 10/2022 - 03/2011
21	Stomach Neoplasms (Stomach Cancer) 06/2022 - 01/2018
19	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 11/2018
11	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2003
8	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2015
5	Microsatellite Instability 01/2022 - 11/2018
5	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 11/2021 - 01/2020
4	Disease Progression 01/2022 - 01/2003
2	Fever (Fevers) 12/2021 - 01/2018
2	Colonic Neoplasms (Colon Cancer) 07/2021 - 01/2017
2	Neutropenia 01/2021 - 12/2019
2	Residual Neoplasm 12/2020 - 01/2019
2	Triple Negative Breast Neoplasms 01/2019 - 07/2012
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 06/2022
1	Lymphatic Metastasis 04/2022
1	Amyloid Plaque 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2022
1	Adenocarcinoma 01/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 12/2021
1	Fatigue 12/2021
1	Hypopituitarism (Sheehan's Syndrome) 12/2021
1	Hypothyroidism 12/2021
1	Cholangiocarcinoma 10/2021
1	Exanthema (Rash) 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Anemia 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Necrosis 12/2020

Drug/Important Bio-Agent (IBA)

14	Circulating Tumor DNAIBA 04/2022 - 11/2018
9	Biomarkers (Surrogate Marker)IBA 04/2022 - 11/2018
7	Immune Checkpoint InhibitorsIBA 09/2022 - 11/2018
6	pembrolizumabIBA 01/2022 - 01/2020
6	Trastuzumab (Herceptin)FDA Link 01/2022 - 12/2010
5	human ERBB2 proteinIBA 01/2022 - 11/2014
5	NivolumabIBA 01/2022 - 01/2019
4	Monoclonal AntibodiesIBA 06/2021 - 01/2019
4	Irinotecan (Camptosar)FDA LinkGeneric 06/2021 - 01/2020
4	Hormones (Hormone)IBA 01/2018 - 01/2016
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2018
3	lenvatinibIBA 01/2022 - 01/2020
3	trifluridine tipiracil drug combinationIBA 07/2021 - 12/2019
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2021 - 02/2019
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 12/2010
2	trastuzumab deruxtecanIBA 06/2022 - 01/2021
2	regorafenibIBA 01/2022 - 01/2021
2	Formaldehyde (Formol)FDA Link 01/2022 - 01/2018
2	ParaffinIBA 01/2022 - 01/2018
2	pertuzumabIBA 01/2022 - 11/2021
2	Tumor Biomarkers (Tumor Markers)IBA 10/2021 - 07/2021
2	Capecitabine (Xeloda)FDA Link 07/2021 - 02/2019
2	Cell-Free Nucleic AcidsIBA 03/2021 - 12/2019
2	Bevacizumab (Avastin)FDA Link 01/2021 - 12/2019
2	Estrogen ReceptorsIBA 01/2021 - 11/2014
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2020
2	Taxoids (Taxanes)IBA 01/2020 - 09/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2020
2	AnthracyclinesIBA 09/2017 - 03/2012
2	Aromatase InhibitorsIBA 11/2016 - 03/2011
1	Notch ReceptorsIBA 10/2022
1	Pharmaceutical PreparationsIBA 06/2022
1	Amyloid (Amyloid Fibrils)IBA 01/2022
1	CateninsIBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Vitamin D FDA LinkGeneric 01/2022
1	AntibodiesIBA 01/2022
1	hydroxide ionIBA 01/2022
1	Hematoxylin (Haematoxylon)IBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Hydrocortisone (Cortisol)FDA LinkGeneric 12/2021
1	Docetaxel (Taxotere)FDA Link 12/2021
1	Blood Glucose (Blood Sugar)IBA 12/2021
1	Thyroxine (Levothyroxine)FDA LinkGeneric 12/2021
1	Small Cytoplasmic RNAIBA 11/2021
1	Programmed Cell Death 1 ReceptorIBA 10/2021
1	Panitumumab (Vectibix)FDA Link 06/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	DeoxyuridineIBA 01/2021
1	dUTP pyrophosphataseIBA 01/2021
1	fms-Like Tyrosine Kinase 3IBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	TAS-114IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2020

Therapy/Procedure

28	Therapeutics 01/2022 - 01/2003
15	Drug Therapy (Chemotherapy) 10/2022 - 12/2010
8	Precision Medicine 01/2022 - 09/2018
5	Adjuvant Chemotherapy 12/2021 - 09/2017
3	Immunotherapy 01/2022 - 01/2019
3	Hepatectomy 12/2021 - 05/2002
2	Neoadjuvant Therapy 01/2022 - 01/2019
2	Molecular Targeted Therapy 01/2022 - 01/2022
2	Gastrectomy 12/2021 - 02/2019
2	Genomic Medicine 02/2021 - 09/2018
1	Lymph Node Excision (Lymph Node Dissection) 04/2022
1	Aftercare (After-Treatment) 04/2022
1	Transplantation 01/2021
1	Combination Drug Therapy (Combination Chemotherapy) 01/2020
1	Radiotherapy 01/2020